SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

31 Jan 2024 Evaluate
The revenue zoomed 24.05% to Rs. 10852.90 millions for the quarter ended December 2023 as compared to Rs. 8748.90 millions during the corresponding quarter last year.Profit after tax for the quarter ended December 2023 reported a huge growth of 77.60% to Rs. 2201.50  millions from Rs. 1239.60 millions.Operating Profit saw a handsome growth to 3409.10 millions from 1899.20 millions in the quarter ended December 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202312 202212 % Var 202312 202212 % Var 202303 202203 % Var
Sales 10852.90 8748.90 24.05 30450.50 25624.10 18.84 34112.70 31406.40 8.62
Other Income 137.30 305.10 -55.00 973.50 1443.00 -32.54 1327.50 1397.30 -5.00
PBIDT 3409.10 1899.20 79.50 9750.80 6507.50 49.84 8320.30 10306.20 -19.27
Interest 23.60 26.80 -11.94 53.80 40.20 33.83 52.30 91.20 -42.65
PBDT 3385.50 1872.40 80.81 9697.00 6467.30 49.94 8268.00 10215.00 -19.06
Depreciation 334.10 322.90 3.47 986.90 948.40 4.06 1269.50 1209.60 4.95
PBT 3051.40 1549.50 96.93 8710.10 5518.90 57.82 6998.50 9005.40 -22.29
TAX 849.90 309.90 174.25 2264.60 1103.80 105.16 1411.30 1806.80 -21.89
Deferred Tax 30.50 134.60 -77.34 87.10 55.20 57.79 -29.30 95.10 -130.81
PAT 2201.50 1239.60 77.60 6445.50 4415.10 45.99 5587.20 7198.60 -22.38
Equity 252.70 257.10 -1.71 252.70 257.10 -1.71 252.70 171.70 47.18
PBIDTM(%) 31.41 21.71 44.70 32.02 25.40 26.09 24.39 32.82 -25.67

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×